(S)-Roscovitine
Based on 1 publication(s) in Google Scholar
(S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier CDKs inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.15%
- No. CAS: 186692-45-5
- Fòrmula: C19H26N6O
- Peso molecular:354.45
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (S)-Roscovitine
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
CDK1 ≤1 μM (IC50) |
CDK2 ≤1 μM (IC50) |
CDK5 ≤1 μM (IC50) |
CDK7 ≤1 μM (IC50) |
CDK9 ≤1 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Oocyte | IC50 |
0.8 μM
Compound: 25
|
Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.
Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.
|
[PMID: 9046330] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:20-25 g, P60 male C57 b/6 mice[2]
-
Dosage:25 mg/kg
-
Administration:I.p.; at 15 min before and 1 hr after pMCAo
-
Result:Decreased of the total infarct volume.
Chemical Information
-
No. CAS 186692-45-5
-
Appearance Solid
-
Peso molecular 354.45
-
Fòrmula C19H26N6O
-
Color White to off-white
-
SMILES
CC[C@H](NC1=NC(NCC2=CC=CC=C2)=C3N=CN(C(C)C)C3=N1)CO
-
Synonyms
(S)-Seliciclib; (S)-CYC202
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Neuropathol Exp Neurol
Downregulating Cdk5 reverses hippocampal neuron ferroptosis by regulating the AMP-activated protein kinase pathway and "M1" polarized microglia. [Abstract]2025 Aug 19:nlaf092. PMID: 40829042
Solvente y solubilidad
In Vitro:
DMSO : 50 mg/mL (141.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (14.11 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Le Roy L, et al. Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells. Cells. 2021 Jan 8;10(1):104. [Content Brief]
[2]. Menn B, et al. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One. 2010 Aug 12;5(8):e12117. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8213 mL | 14.1064 mL | 28.2127 mL | 70.5318 mL |
| 5 mM | 0.5643 mL | 2.8213 mL | 5.6425 mL | 14.1064 mL | |
| 10 mM | 0.2821 mL | 1.4106 mL | 2.8213 mL | 7.0532 mL | |
| 15 mM | 0.1881 mL | 0.9404 mL | 1.8808 mL | 4.7021 mL | |
| 20 mM | 0.1411 mL | 0.7053 mL | 1.4106 mL | 3.5266 mL | |
| 25 mM | 0.1129 mL | 0.5643 mL | 1.1285 mL | 2.8213 mL | |
| 30 mM | 0.0940 mL | 0.4702 mL | 0.9404 mL | 2.3511 mL | |
| 40 mM | 0.0705 mL | 0.3527 mL | 0.7053 mL | 1.7633 mL | |
| 50 mM | 0.0564 mL | 0.2821 mL | 0.5643 mL | 1.4106 mL | |
| 60 mM | 0.0470 mL | 0.2351 mL | 0.4702 mL | 1.1755 mL | |
| 80 mM | 0.0353 mL | 0.1763 mL | 0.3527 mL | 0.8816 mL | |
| 100 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7053 mL |
(S)-Roscovitine Related Classifications
HY-112403 Related Classifications
Powered by Bioz